Phil Pharma Wealth, Inc. Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Phil Pharma Wealth, Inc. Pharmaceutical Import Records from India — 2 Products, $237.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Phil Pharma Wealth, Inc. — Pharmaceutical Importer Profile (2026) | 2 Products, $237.7K Trade | TransData Nexus

Phil Pharma Wealth, Inc.

Pharmaceutical Importer · Philippines · Advanced Antibiotics Focus · $237.7K Total Trade · DGFT Verified

Phil Pharma Wealth, Inc. is a pharmaceutical importer based in Philippines with a total trade value of $237.7K across 2 products in 1 therapeutic categories. Based on 19 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Phil Pharma Wealth, Inc. sources from 1 verified Indian supplier, with Karnataka Antibiotics And Pharmaceuticals Limited accounting for 100.0% of imports.

Phil Pharma Wealth, Inc. — Import Portfolio & Supplier Network

Phil Pharma Wealth, Inc. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Phil Pharma Wealth, Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Karnataka Antibiotics And Pharmaceuticals Limited	$992.0K	53	100.0%

Phil Pharma Wealth, Inc. sources from 1 verified Indian supplier across 28 distinct formulations. The sourcing is highly concentrated — Karnataka Antibiotics And Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Ceftriaxone (as sodium )1g powder for injection (im/iv)+diluent roxon Each vialcontains ceftriaxone sodium	$134.0K	4
Ceftriaxone sodium 1g powder for	$100.0K	2
Hydrocortisone (as sodium succinate) 250MG powder for INJ (im/iv) stericort Each vial contains:hydrocortisone 250 MG	$71.6K	2
Amikacin sulphate INJ,USP	$65.5K	2
Tramadol hydrochloride injection 50MG/ML	$62.9K	6
Hydrocortisone (as sodium succinate) 100MG powder for INJ (im/iv) stericort,eachvial contains:hydrocortisone 100 MG	$53.0K	3
Hydrocortisone(as sodium succinate)250MG	$50.0K	1
Benzathine benzylpenicillin 1.2 m	$40.3K	2
Hydrocortisone(as sodium succinate)100	$38.8K	1
Furosemide 10MG/ML solutions for	$37.8K	1
Hydrocortisone(as sodium succinate)100MG	$33.4K	1
Furosemide 10MG/ML solution for injection (im/iv) 2ML Each ML contains:furosemide BP 10MG.	$32.9K	1
Furosemide 10MG/ML solution for injection (im/iv) 2ML Each ML contains:furosemide BP 10 MG.	$32.9K	1
Hydrocortisone (as sodium succinate)	$30.6K	3
Amikacin (as sulfate) 125 MG/ML solutionfor injection (im/iv) cinmik Each vialcontains:amikacin (as sulphate	$28.7K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amikacin	Advanced Antibiotics	$163.4K	11	0.8%	15
2	Benzylpenicillin	Advanced Antibiotics	$74.3K	8	1.9%	6

Phil Pharma Wealth, Inc. imports 2 pharmaceutical products across 1 categories into Philippines totaling $237.7K.

Phil Pharma Wealth, Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Phil Pharma Wealth, Inc. is a 100% Filipino-owned pharmaceutical company established on February 10, 1993, in response to the Philippine government's Generics Act of 1988, which aimed to provide affordable and quality medicines to the public. The company is headquartered at Suite 3001, 30th Floor, Tektite East Tower, Ortigas Center, Pasig City, Metro Manila. Phil Pharma Wealth, Inc. is licensed by the Securities and Exchange Commission and the Food and Drug Administration (FDA) of the Philippines to import and distribute a wide range of medical products, including finished pharmaceutical formulations such as tablets, capsules, syrups, injections, and medical devices. (philjobnet.gov.ph)

Over the years, the company has expanded its product portfolio to include over 300 items, with a particular focus on life-saving injectable products. This strategic emphasis aligns with the company's mission to enhance healthcare access across the Philippines by providing a one-stop solution for pharmaceutical needs, underpinned by a deep commitment to quality, affordability, and service excellence.

2Distribution Network

Phil Pharma Wealth, Inc. operates a centralized distribution model from its headquarters in Pasig City, Metro Manila. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's extensive product portfolio and focus on timely deliveries suggest a well-established distribution network capable of serving pharmacies, hospitals, and healthcare facilities throughout the Philippines. The company's strategic location in Metro Manila positions it advantageously to manage and distribute pharmaceutical products efficiently across the archipelago.

3Industry Role

Phil Pharma Wealth, Inc. functions primarily as a pharmaceutical importer and wholesaler within the Philippine healthcare supply chain. By importing a diverse range of finished pharmaceutical formulations, including life-saving injectables, the company plays a crucial role in ensuring the availability of essential medicines across the country. Its focus on high-quality, affordable products positions it as a key player in the wholesale pharmaceutical market, catering to the needs of various healthcare providers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Phil Pharma Wealth, Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Phil Pharma Wealth, Inc. demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical products from a single supplier: Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This exclusive sourcing strategy has resulted in a total import value of $238,000 USD over 19 shipments, with the top two products—Amikacin and Benzylpenicillin—accounting for 100% of the import value. While this concentration may offer benefits such as streamlined procurement processes and potentially favorable pricing, it also exposes the company to risks associated with supply chain disruptions, regulatory changes, or quality issues from the sole supplier. The absence of alternative suppliers could impact the company's ability to maintain a consistent supply of critical pharmaceutical products.

2Supply Chain Resilience

The resilience of Phil Pharma Wealth, Inc.'s supply chain is closely tied to its exclusive relationship with Karnataka Antibiotics and Pharmaceuticals Limited (KAPL). The lack of backup suppliers and the concentration on a limited number of formulations may pose challenges in the event of supply disruptions, regulatory changes, or quality control issues with KAPL. Additionally, the company's reliance on a single supplier for all its imports may limit its ability to diversify its product offerings or respond flexibly to changing market demands. To enhance supply chain resilience, it would be prudent for Phil Pharma Wealth, Inc. to consider establishing relationships with additional suppliers and diversifying its product portfolio.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

The Food and Drug Administration (FDA) of the Philippines is the primary regulatory authority overseeing the importation, registration, and distribution of pharmaceutical products in the country. The FDA operates under the Department of Health and is responsible for ensuring the safety, efficacy, and quality of health products. Key legislation governing pharmaceutical imports includes the Food, Drug, and Cosmetic Act (Republic Act No. 3720), as amended by the FDA Act of 2009 (Republic Act No. 9711), which provides the legal framework for the regulation of health products in the Philippines.

2Import Licensing & GMP

Importers of pharmaceutical products in the Philippines must obtain a License to Operate (LTO) from the FDA, which authorizes them to import and distribute health products. Additionally, pharmaceutical products intended for importation must be registered with the FDA, ensuring they meet the required safety, efficacy, and quality standards. The FDA recognizes Good Manufacturing Practice (GMP) certificates from reputable authorities, including the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), facilitating the importation of products manufactured under these standards.

Quality & Labeling

Phil Pharma Wealth, Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Phil Pharma Wealth, Inc. has strategically focused on importing life-saving injectable products, including cephalosporins, penicillins and derivatives, aminoglycosides, anesthetic agents, antipsychotic agents, bronchodilators, and uterine stimulants. This focus aligns with the company's mission to provide affordable and quality medicines, particularly in critical therapeutic areas, thereby addressing the healthcare needs of the Filipino population. The emphasis on injectables reflects the company's commitment to offering essential medicines that are vital for patient care and survival. (philjobnet.gov.ph)

2Sourcing Profile

Phil Pharma Wealth, Inc. primarily sources its pharmaceutical products from Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) in India. This sourcing strategy involves importing finished pharmaceutical formulations, including injectables, which are then distributed within the Philippine market. The company's focus on sourcing from a single supplier may offer benefits such as streamlined procurement processes and potentially favorable pricing; however, it also exposes the company to risks associated with supply chain disruptions and regulatory changes affecting the sole supplier.

3Market Positioning

Seller's Guide — How to Become a Supplier to Phil Pharma Wealth, Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Phil Pharma Wealth, Inc. by offering alternative products or formulations that could diversify the company's portfolio and reduce dependency on a single supplier. Establishing such partnerships could enhance the resilience and competitiveness of both parties in the Philippine pharmaceutical market. Additionally, Indian exporters can explore opportunities to supply products that align with the therapeutic areas emphasized by Phil Pharma Wealth, Inc., such as injectables and life-saving medications.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to Phil Pharma Wealth, Inc. and the Philippine market must ensure that their products are registered with the FDA of the Philippines and manufactured in compliance with recognized Good Manufacturing Practice (GMP) standards, such as those from the EU, WHO, or PIC/S. Additionally, exporters must obtain a License to Operate (LTO) from the FDA, which authorizes them to import and distribute health products within the Philippines. Compliance with these regulatory requirements is essential for successful market entry and distribution.

How to Approach

Frequently Asked Questions — Phil Pharma Wealth, Inc.

What products does Phil Pharma Wealth, Inc. import from India?

Phil Pharma Wealth, Inc. imports 2 pharmaceutical products across 1 categories. Top imports: Amikacin ($163.4K), Benzylpenicillin ($74.3K).

Who supplies pharmaceuticals to Phil Pharma Wealth, Inc. from India?

Phil Pharma Wealth, Inc. sources from 1 verified Indian suppliers. The primary supplier is Karnataka Antibiotics And Pharmaceuticals Limited (100.0% of imports, $992.0K).

What is Phil Pharma Wealth, Inc.'s total pharmaceutical import value?

Phil Pharma Wealth, Inc.'s total pharmaceutical import value from India is $237.7K, based on 19 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Phil Pharma Wealth, Inc. focus on?

Phil Pharma Wealth, Inc. imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Phil Pharma Wealth, Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.